Gordon J N, Goggin P M
Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton.
Postgrad Med J. 2003 Mar;79(929):127-32. doi: 10.1136/pmj.79.929.127.
Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to be active in a wide variety of inflammatory and malignant disorders where conventional therapies have failed. Recently, considerable progress has been made in elucidating its complex mechanisms of action, which include both anticytokine and antiangiogenic properties. However, in addition to its well known teratogenic potential, it has a significant side effect profile that leads to cessation of treatment in up to 30% of subjects. In response to this, two new classes of potentially safer and non-teratogenic derivatives have recently been developed. This review summarises the biological effects, therapeutic applications, safety profile, and future potential of thalidomide and its derivatives.
在全球撤市四十年后，沙利度胺目前正作为一种新型强效免疫调节剂经历显著复兴。在过去十年中，人们发现它在多种传统疗法无效的炎症性和恶性疾病中具有活性。最近，在阐明其复杂作用机制方面取得了相当大的进展，其作用机制包括抗细胞因子和抗血管生成特性。然而，除了其众所周知的致畸潜力外，它还有显著的副作用，导致高达30%的受试者停止治疗。对此，最近已开发出两类潜在更安全且无致畸性的新型衍生物。本综述总结了沙利度胺及其衍生物的生物学效应、治疗应用、安全性概况和未来潜力。
